ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents and targeted therapies.
ASLAN Pharmaceuticals has raised $5.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in March 2024.
ASLAN Pharmaceuticals's investors include Vivo Capital, Daiwa Corporate Investment, K2 HealthVentures, Surveyor Capital, Morningside.
ASLAN Pharmaceuticals is headquartered in Singapore, Singapore.
ASLAN Pharmaceuticals is an oncology-focused biotechnology company developing a portfolio of immuno-oncology agents and targeted therapies.
ASLAN Pharmaceuticals is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ASLAN Pharmaceuticals — Funding & Investors." VCBacked, March 12, 2024, https://www.vcbacked.co/company/aslan-pharmaceuticals. Accessed July 20, 2026.
VCBacked. (2024). ASLAN Pharmaceuticals — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/aslan-pharmaceuticals
{{cite web |title=ASLAN Pharmaceuticals — Funding & Investors |url=https://www.vcbacked.co/company/aslan-pharmaceuticals |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated